Navigation Links
Study using stem cells to improve organ transplantation to receive $12 million
Date:11/7/2013

CHICAGO An innovative Northwestern Medicine research program investigating if stem cells may be the key to allowing organ transplant patients to stop taking immunosuppressive drugs has received $12 million in research funding. The grant will allow researchers to finish Phase II of the clinical trials and begin Phase III. Northwestern began the study's clinical trial in early 2009 as part of a partnership with the University of Louisville, which engineers the specialized stem cells used in each transplant procedure.

"During our clinical trials, we have been able to take the novel stem cell technology that the University of Louisville pioneered from the bench to the bedside," said Joseph Leventhal, MD PhD, director of kidney and pancreas transplantation at Northwestern Memorial Hospital, and professor of Surgery at Northwestern University Feinberg School of Medicine. "The results of our clinical trial were a catalyst for Novartis' long-term investment in this new cellular based therapy for solid organ transplantation."

The clinical trial uses specially engineered stem cells from kidney donors to make the organ recipient's immune system recognize the new kidney as its own. In mainstream transplant procedures, a recipient faces the danger of their immune system treating a newly transplanted organ as a foreign body that should be removed, causing it to attack and try to kill the new organ. To prevent a recipient's immune system from attacking their new organ, doctors must currently prescribe toxic anti-rejection medicines to weaken the immune system and keep it at bay.

In March of 2012, Leventhal and his colleagues published the study's initial clinical results from eight participants in Science Translational Medicine. The article outlined that of the study's eight participants, five were able to successfully stop taking all anti-rejection medicines in just one year after they received a new kidney, and two required only low-doses of anti-rejection medicine to be maintained instead of a normal regimen. The final patient suffered an unrelated illness that required another kidney transplant to be performed.

"Northwestern's Comprehensive Transplant Center has demonstrated for the first time in the history of organ transplantation that we can safely achieve durable transplantation tolerance in mismatched and unrelated donor/recipient combinations," said Leventhal. "I am very excited to be able to continue this groundbreaking translational research."

The first subjects to participate in the research study underwent surgery on February 26, 2009. To date, more than 20 patients have been enrolled and have received new kidneys as part of the clinical trial, the majority of which have been successfully taken off of all anti-rejection medicines. In order to qualify, the donor and recipient pairs must be blood-type compatible and have a negative cross-match, which means that testing has been done to confirm the recipient does not have antibodies in the blood that would cause rejection of the kidney.

The grant is a result of a license and research collaboration agreement between Regenerex LLC and Novartis to provide access to the novel technology developed by the University of Louisville's Institute for Cellular Therapeutics. Leventhal does not receive financial incentives or payment from Novartis or Regenerex LLC.


'/>"/>

Contact: Bret Coons
bcoons@nmh.org
312-926-2955
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
2. Study finds that Americans want doctors guidance on genetic test results
3. New study assesses injuries seen in the emergency department to children of teenage parents
4. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
5. Independent Naturopathic Clinic Receives Groundbreaking Research Grant: Partners with Global Pharmaceutical Company to Study Relief of Cancer Drug Side Effects
6. 20 percent of nations GME funds go to New York while 29 states get less than 1 percent, study says
7. Physician shortage could be cut by new primary care models, study finds
8. Study: Access to health care increases prescription opioid availability and associated abuse
9. Study: Higher rates of diabetes, hypertension, heart disease and stroke found in food desert
10. U-M study: Smarter blood pressure guidelines could prevent many more heart attacks and strokes
11. Study looks at safety, effectiveness of generics for treating depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... SARASOTA, Fla. (PRWEB) , ... September 17, 2019 ... ... plans and Dental Service Organizations (DSOs) has earned Michael Cole, Vice President of ... presented today by the National Association of Dental Plans (NADP) at their annual ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... join the largest accountable care organization (ACO) in the country, the company announced ... groundbreaking collaboration to improve care quality and increase cost efficiency. This opportunity is ...
(Date:9/17/2019)... ... September 17, 2019 , ... Genomenon ... , with the goal of providing resources to assist researchers and encourage pharmaceutical ... progressive disease causing abnormal iron deposits in the brain. , BPAN Warriors ...
(Date:9/14/2019)... Okla. (PRWEB) , ... September 14, 2019 , ... ... cannabis industry, has time and again tried to bring the most relevant and important ... ray of hope on an increasingly large number of people across the world suffering ...
(Date:9/11/2019)... ... September 11, 2019 , ... Global Education Group (Global), ... (CME) provider, is the official accreditor for PAINWeek, the largest US pain conference ... topics, as it has done for the past ten years. In addition, the ...
Breaking Medicine News(10 mins):
(Date:9/12/2019)... ... September 12, 2019 , ... ... , revenue cycle management services, integrated practice management, and patient engagement solutions, ... Sponsor at National User Conference (NUCON) 2019 . The annual conference ...
(Date:9/11/2019)... ... September 12, 2019 , ... ... Best Practices, An FDAnews Webinar, Thursday, Sept. 26, 2019, 1:30-3:00 p.m. EDT, ... (DSCSA) implementation requirements? Is the company clear on nuances of the guidelines regulating ...
(Date:9/11/2019)... ... September 11, 2019 , ... Radiology… gastroenterology… ophthalmology… pathology… , ... evaluate medical images. In fact, image analysis software represents one of the fastest-growing ... to AI-based image analysis, one will be left behind. , As both a ...
Breaking Medicine Technology: